Physician profile
Nirav C Shah
NPI 1245260066
$25,317.16
in general payments reported to CMS, 2019-2025
11 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,315 · 2020: $3,678 · 2021: $5,114 · 2022: $8,204 · 2023: $31.86 · 2024: $1,875 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $132.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $12,325.85 | 2019-2021 | |
| Kite Pharma, INC. | $10,530.52 | 2019-2022 | |
| Beigene USA, INC. | $1,875.00 | 2024 | Brukinsa |
| Abbott Laboratories | $128.72 | 2019 | |
| Adc Therapeutics America, INC. | $100.38 | 2025 | |
| Allergan, INC. | $86.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.85 | 2019 | |
| Lundbeck LLC | $73.49 | 2019 | |
| Amneal Pharmaceuticals LLC | $61.60 | 2021-2022 | |
| Abbvie INC. | $31.86 | 2023 | Botox |
| Terumo Medical Corporation | $17.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.